Package Leaflet: Information for the User
Ultracain with Adrenaline 40 mg/ml + 10 micrograms/ml Solution for Injection
Articaine hydrochloride / Epinephrine
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
|
Contents of the Package Leaflet
Contents of the pack and other information
Ultracain with Adrenaline 40 mg/ml + 10 micrograms/ml Solution for Injection is used to numb (anesthetize) the oral cavity during dental procedures.
This medicine contains two active substances:
Your dentist will administer Ultracain with Adrenaline 40 mg/ml + 5 micrograms/ml Solution for Injection or Ultracain with Adrenaline 40 mg/ml + 10 micrograms/ml Solution for Injection.
Ultracain is indicated in children over 4 years (approximately 20 kg body weight), adolescents, and adults.
Depending on the type of dental procedure performed, the dentist will choose one of the two medicines:
Do not use Ultracain with Adrenaline 40 mg/ml + 10 micrograms/ml Solution for Injection if you have any of the following conditions:
Warnings and precautions
Talk to your dentist before starting to use Ultracain with Adrenaline 40 mg/ml + 10 micrograms/ml Solution for Injection if you have any of the following conditions:
Using Ultracain with Adrenaline 40 mg/ml + 10 micrograms/ml Solution for Injection with other medicines
Tell your dentist if you are taking, have recently taken, or might take any other medicine.
It is very important to inform your dentist if you are taking any of the following medicines:
Using Ultracain with Adrenaline 40 mg/ml + 10 micrograms/ml Solution for Injection with food
Avoid eating, even chewing gum, until you have regained normal sensation. Otherwise, there is a risk that you may bite your lips, cheeks, or tongue, especially in children.
Pregnancy, Breast-feeding, and Fertility
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your dentist or doctor for advice before using this medicine.
Your dentist or doctor will decide whether you can take Ultracain with Adrenaline 40 mg/ml + 10 micrograms/ml Solution for Injection during pregnancy.
Breast-feeding can be resumed 5 hours after anesthesia.
No adverse effects on fertility are expected with the doses used in a dental procedure.
Driving and Using Machines
If you experience side effects, including dizziness, blurred vision, or fatigue, do not drive or operate machinery until you have recovered (usually within 30 minutes after the dental procedure).
Ultracain with Adrenaline 40 mg/ml + 10 micrograms/ml Solution for Injection contains sodium and sodium metabisulfite.
If there is a risk of an allergic reaction, your dentist will choose another medicine for anesthesia.
Only doctors and dentists are trained to use Ultracain with Adrenaline 40 mg/ml + 10 micrograms/ml Solution for Injection.
Your dentist will choose between Ultracain with Adrenaline 40 mg/ml + 5 micrograms/ml Solution for Injection or Ultracain with Adrenaline 40 mg/ml + 10 micrograms/ml Solution for Injection and determine the appropriate dose based on your age, weight, general health, and dental procedure.
The lowest dose that provides effective anesthesia should be used.
This medicine is administered by slow injection into the oral cavity.
If you use more Ultracain with Adrenaline 40 mg/ml + 10 micrograms/ml Solution for Injection than you should
It is unlikely that you will be given too much of this injection, but if you start to feel unwell, tell your dentist. Symptoms of an overdose include acute weakness, pale skin, headache, agitation or restlessness, disorientation, loss of balance, tremors or involuntary twitching, dilated pupils, blurred vision, difficulty focusing, speech disturbances, dizziness, convulsions, stupor, loss of consciousness, coma, yawning, abnormally slow or rapid breathing that can lead to temporary respiratory arrest, and heart failure.
If you have any further questions on the use of this medicine, ask your dentist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
When you are in the dentist's office, the dentist will closely monitor the effects of Ultracain with Adrenaline 40 mg/ml + 10 micrograms/ml Solution for Injection.
Tell your dentist, doctor, or pharmacist immediately if you experience any of the following serious side effects:
These side effects are rare (may affect up to 1 in 1,000 people).
Other side effects may also occur in some patients.
Common side effects: may affect up to 1 in 10 people:
Uncommon side effects: may affect up to 1 in 100 people:
Rare side effects: may affect up to 1 in 1,000 people:
Very rare side effects: may affect up to 1 in 10,000 people:
Frequency not known: cannot be estimated from the available data
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date is the last day of the month stated.
Store below 25°C.
Do not freeze.
Keep the cartridges in the outer packaging, which is hermetically sealed to protect from light.
Do not use this medicine if you notice that the solution is cloudy or has changed color.
The cartridges are for single use. Use immediately after opening the cartridge. Unused solution should be discarded.
Medicines should not be disposed of via wastewater or household waste. Your dentist will know how to dispose of medicines that are no longer needed. This will help protect the environment.
Composition of Ultracain with Adrenaline40 mg/ml + 10 micrograms/ml injectable solution
Product Appearance and Container Content
Ultracain with adrenaline 40 mg/ml + 10 micrograms/ml injectable solution is colorless.
It is packaged in single-use glass cartridges, sealed at the base with a movable rubber piston and at the top with a rubber seal held by an aluminum cap.
Container containing one cartridge and a leaflet.
Container containing 100 cartridges (clinical packaging) in 10 PVC blister packs with 10 cartridges each and a leaflet.
Other presentations:
Ultracain with adrenaline 40 mg/ml + 5 micrograms/ml injectable solution.
Marketing Authorization Holder and Manufacturer
LABORATORIOS NORMON, S.A.
Ronda de Valdecarrizo, 6 – 28760 Tres Cantos – Madrid (SPAIN)
Date of last revision of this leaflet: October 2024.
Other Sources of Information
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es.
You can access detailed and updated information about this medicinal product by scanning the QR code included in the leaflet and packaging with your mobile phone (smartphone). You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/55033/P_55033.html
This information is intended solely for healthcare professionals:
Posology
For all populations, the lowest dose that provides effective anesthesia should be used. The necessary dose must be determined individually.
For a routine procedure, the normal dose for adult patients is 1 cartridge, but the content of less than one cartridge may be sufficient for effective anesthesia. According to the dentist's judgment, more cartridges may be required for more extensive procedures, without exceeding the recommended maximum dose.
In the case of most routine dental procedures, it is preferable to use Ultracain with adrenaline 40 mg/ml + 5 micrograms/ml injectable solution.
For more complex procedures, such as pronounced hemostasis, it is preferable to use Ultracain with adrenaline 40 mg/ml + 10 micrograms/ml injectable solution.
Concomitant use of sedatives to reduce patient anxiety:
The maximum safe dose of the local anesthetic may be reduced in sedated patients due to an additive effect on central nervous system depression.
Adults and adolescents (between 12 and 18 years old)
In adults and adolescents, the maximum dose of articaine is 7 mg/kg, with an absolute maximum dose of articaine of 500 mg. The maximum dose of articaine of 500 mg corresponds to a healthy adult weighing over 70 kg.
Children (between 4 and 11 years old)
The safety of Ultracain with adrenaline 40 mg/ml + 10 micrograms/ml injectable solution has not been established in children under 4 years old. No data are available.
The amount to be injected must be determined based on the child's age and weight and the magnitude of the operation. The effective median dose is 2 mg/kg and 4 mg/kg for simple and complex procedures, respectively. The lowest dose that provides effective dental anesthesia should be used. In children from 4 years old (or from 20 kg (44 lbs) of body weight) and older, the maximum dose of articaine is only 7 mg/kg, with an absolute maximum dose of 385 mg of articaine for a healthy child weighing 55 kg.
Special Populations
Elderly patients and patients with renal disorders:
Due to the lack of clinical data, special precautions should be taken to administer the lowest dose that provides effective anesthesia in elderly patients and in patients with renal disorders.
High plasma levels of the medicinal product may occur in these patients, especially after repeated use. In case of re-injection, the patient should be strictly monitored to identify any signs of relative overdose.
Patient with hepatic impairment
For patients with hepatic impairment, special precautions should be taken to administer the lowest dose that provides effective anesthesia, especially after repeated use, although 90% of articaine is first inactivated by non-specific plasma esterases of tissues and blood.
Patient with plasma cholinesterase deficiency
High plasma levels of the medicinal product may occur in patients with plasma cholinesterase deficiency or under treatment with acetylcholinesterase inhibitors, since the product is inactivated by 90% by plasma esterases. Therefore, the lowest dose that provides effective anesthesia should be used.
Method of Administration
Infiltration and perineural use in the oral cavity.
If there is inflammation and/or infection at the injection site, local anesthesia should be injected with caution. The injection rate should be very slow (1 ml/min).
Precautions to be taken before handling or administering the medicinal product
This medicinal product should only be used by a doctor or a dentist with sufficient training and familiar with the diagnosis and treatment of systemic toxicity, or under their supervision. Before inducing regional anesthesia with local anesthetics, it should be ensured that resuscitation equipment and adequate medication are available to provide immediate treatment for any respiratory or cardiovascular emergency. The patient's level of consciousness should be monitored after each injection of local anesthesia.
When using Ultracain with adrenaline 40 mg/ml + 10 micrograms/ml injectable solution for infiltration or regional anesthetic block, the injection should always be administered slowly and with prior aspiration.
Special Warnings
Adrenaline reduces blood flow to the gums, which can cause local tissue necrosis.
Very rare cases of prolonged or irreversible nerve damage and taste loss have been reported after mandibular block anesthesia.
Precautions for Use
Risk associated with accidental intravascular injection:
An accidental intravascular injection can cause high levels of adrenaline and articaine in the systemic circulation. This may be associated with serious adverse reactions, such as convulsions, followed by central nervous system depression and cardiorespiratory arrest, which progresses to respiratory and circulatory arrest.
Therefore, to ensure that the needle does not penetrate a blood vessel during injection, aspiration should be performed before injecting the local anesthetic. However, the absence of blood in the syringe does not guarantee that intravascular injection has not occurred.
Risk associated with intraneural injection:
An accidental intraneural injection can cause the drug to move retrogradely through the nerve.
To avoid intraneural injection and prevent nerve damage when performing nerve blocks, the needle should be slightly withdrawn whenever the patient feels a sensation of discharge during injection or if the injection is particularly painful. If nerve damage occurs due to the needle, the neurotoxic effect may be worsened by the possible chemical neurotoxicity of articaine and the presence of adrenaline, as it may reduce perineural blood flow and prevent local elimination of articaine.
Treatment of Overdose
Before administering regional anesthesia with local anesthetics, it should be ensured that resuscitation equipment and adequate medication are available to provide immediate treatment for any respiratory or cardiovascular emergency.
Depending on the severity of the overdose symptoms, the doctor or dentist should implement protocols that anticipate the need to protect the airways and provide assisted ventilation.
The patient's level of consciousness should be monitored after each injection of local anesthesia.
If signs of acute systemic toxicity appear, the injection of the local anesthetic should be stopped immediately. If necessary, the patient should be placed in a supine position.
Symptoms of the CNS (convulsions, CNS depression) should be treated immediately with adequate respiratory support and administration of anticonvulsant drugs.
Optimal oxygenation and ventilation, along with circulatory support and treatment of acidosis, can prevent cardiac arrest.
If cardiovascular depression (hypotension, bradycardia) occurs, appropriate treatment with intravenous fluids, vasopressors, or inotropic agents should be considered. Children should be administered doses according to their age and weight.
In case of cardiac arrest, cardiopulmonary resuscitation should be performed immediately.
Special Precautions for Disposal and Other Handling
This medicinal product should not be used if the solution is turbid or has changed color.
To avoid the risk of infection (e.g., transmission of hepatitis), the syringe and needles used to prepare the solution should always be new and sterile.
The cartridges are for single use. If only part of the cartridge is used, the rest should be discarded.
Disposal of the unused medicinal product and all materials that have come into contact with it will be carried out in accordance with local regulations.